Mereo BioPharma Group plc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | $10,000 | $— |
| Operating expenses: | ||
| Cost of revenue | (2,574) | 1,146 |
| Research and development | (17,418) | (29,465) |
| General and administrative | (18,424) | (26,107) |
| Loss from operations | (28,416) | (54,426) |
| Other income/(expenses) | ||
| Interest income | 2,131 | 840 |
| Interest expense | (2,881) | (4,175) |
| Changes in the fair value of financial instruments | 245 | 9,286 |
| Foreign currency transaction (loss)/gain, net | (2,347) | 2,723 |
| Other (expenses)/income, net | (10) | 1,086 |
| Benefit from research and development tax credit | 1,280 | 1,728 |
| Net loss before income tax | (29,998) | (42,938) |
| Income tax benefit | 532 | 718 |
| Net loss | $(29,466) | $(42,220) |
| Loss per share – basic and diluted | $(0.04) | $(0.07) |
| Weighted average shares outstanding – basic and diluted | 659,453,921 | 603,196,403 |
| Net loss | $(29,466) | $(42,220) |
| Other comprehensive income/(loss) – Foreign currency transaction adjustments, net of tax | 4,202 | (10,660) |
| Total comprehensive loss | $(25,264) | $(52,880) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.